Drug intelligence / Profile preview

interleukin-18-encoding plasmid DNA

Development stage
Unknown
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intramuscular, Subcutaneous
01

Overview

**interleukin-18-encoding plasmid DNA** is a form of gene therapy that utilizes a plasmid DNA vector encoding the cytokine interleukin-18 (IL-18). After intratumoral or local delivery, the plasmid leads to local production of IL-18 protein, which is a potent inducer of interferon-gamma (IFN-γ) and enhances cytotoxic and immune-modulating activity of CD4^+ T cells, CD8^+ T cells, and NK cells. This therapy is studied primarily for cancer immunotherapy, especially for solid tumors such as hepatic or colon cancer, aiming to stimulate anti-tumor immunity directly in the tumor microenvironment. The mechanism hinges on the induction of a Th1-type immune response and enhancement of IFN-γ-mediated anti-tumor activity.

Other names
IL-18 plasmidIL18 plasmidIL 18 plasmidIL-18-encoding plasmid DNAIL18-encoding plasmid DNAIL 18-encoding plasmid DNAIL-18 gene therapy DNAIL18 gene therapy DNAIL 18 gene therapy DNAinterleukin-18 gene plasmidinterleukin18 gene plasmidinterleukin 18 gene plasmid
02

Targets

IL-18R (Interleukin-18 receptor complex)IFNG (Interferon gamma)IL18 (Interleukin-18)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on interleukin-18-encoding plasmid DNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-18-encoding plasmid DNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call